Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 3/20 | 0.70 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30762678 | 1.00 | TPMT (0.70) | TPMTHCAR1HCAR2POLBTTR | |
| SCHEMBL26334413 | 0.92 | TPMT (0.59) | TPMTHCAR1HCAR2POLBTTR | |
| SCHEMBL7786069 | 0.84 | TPMT (0.46) | TPMTHCAR1ALDH1A1SMN1; SMN2KDR | |
| SCHEMBL29547990 | 0.84 | TPMT (0.46) | TPMTHCAR1ALDH1A1SMN1; SMN2KDR | |
| SCHEMBL23501889 | 0.83 | TTR (0.56) | TPMTHCAR1HCAR2POLBTTR | |
| SCHEMBL475757 | 0.83 | TTR (0.56) | TPMTHCAR1HCAR2POLBTTR | |
| SCHEMBL221684 | 0.83 | TPMT (1.00) | TPMTHCAR1HCAR2POLBRXRA | |
| SCHEMBL8361 | 0.83 | TTR (0.56) | TPMTHCAR1HCAR2POLBTTR | |
| SCHEMBL40661 | 0.83 | TPMT (0.89) | TPMTHCAR1HCAR2RXRARXRB | |
| SCHEMBL19723419 | 0.82 | HTT (0.46) | TPMTHCAR1ALDH1A1SMN1; SMN2SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-10-28 | — | — | US | disclosed |
| EP-4615825-A1 | INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE METHODS OF USE THEREOF | Flagship Pioneering Innovations VI, LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4467199-A2 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2024-11-27 | — | — | EP | disclosed |
| CN-118908957-A | Small molecule inhibitors of NF- κB induced kinase | 詹森药业有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-115073474-B | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024211346-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-3976597-B1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-28 | — | — | EP | disclosed |
| CN-114222737-B | Small molecule inhibitors of NF- κB induced kinase | 詹森药业有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-20 | — | — | US | disclosed |
| US-5866610-A | Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical as inhibitors of the cellular NA+/H+ exchange or as a diagnostic, and pharmaceutical containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-02 | — | — | US | disclosed |
| WO-1998025605-A1 | SPIRO-SUBSTITUTED AZACYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0612723-B1 | Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them | HOECHST AG (DE) | 1997-08-27 | — | — | EP | disclosed |
| EP-0603650-B1 | 3,5-Substituted amino benzoylguanidines, process for their preparation, their use as medicine or diagnostic agent, as well as a medicine containing them | HOECHST AG (DE) | 1997-04-02 | — | — | EP | disclosed |
| US-5516805-A | 3,5-substituted aminobenzoylguanidines, their use as a medicament or diagnostic and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-05-14 | — | — | US | disclosed |
| EP-0702681-A1 | SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS | MERCK & CO. INC. (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994029309-A1 | SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| EP-0612723-A1 | Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-08-31 | — | — | EP | disclosed |
| EP-0603650-A1 | 3,5-Substituted amino benzoylguanidines, process for their preparation, their use as medicine or diagnostic agent, as well as a medicine containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-06-29 | — | — | EP | disclosed |
| US-3953595-A | Substituted benzoic acid hypolipemic agents | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | PDXK, STK25, STK35 | TPMT 931/4885HCAR1 1142/4885HCAR2 1009/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | TPMT 2075/4885HCAR1 623/4885HCAR2 960/4885 |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, IKBKE | TPMT 2009/4885HCAR1 858/4885HCAR2 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.